

Oncology Today with Dr Neil Love: Recently Approved Agents in Multiple Myeloma (Interview Audio)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following drug types best describes the mechanism of action of selinexor, which was recently approved for the treatment of relapsed/refractory (R/R) multiple myeloma (MM)?
 - a. Antibody-drug conjugate
 - b. Inhibitor of the nuclear export protein XPO1
 - c. Anti-CD38 antibody
2. Which of the following proteins is the target on the surface of MM cells at which the antibody-drug conjugate belantamab mafodotin is directed?
 - a. CD38
 - b. PD-L1
 - c. BCMA
3. Which of the following strategies has been recommended as being effective in managing the nausea associated with selinexor/dexamethasone for patients with R/R MM?
 - a. Dose reduction only
 - b. Antiemetic medication only
 - c. Both dose reduction and antiemetic medication
4. The GRIFFIN trial evaluated which of the following agents in combination with lenalidomide, bortezomib and dexamethasone for patients with newly diagnosed MM who are not eligible for transplant?
 - a. Isatuximab
 - b. Selinexor
 - c. Daratumumab